Evaluation of the Immunomodulatory Effects of Radiation for Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme

David Akhavan,Siddharth Subham,John D. Jeppson,Brenda Aguilar,Robyn A. Wong,Jonathan C. Hibbard,Susanta Hui,Jeffrey Y. C. Wong,Stephen J. Forman,Darya Alizadeh,Christine E. Brown

DOI: https://doi.org/10.3390/cells13131075

IF: 6

2024-06-22

Cells

Abstract:Standard-of-care treatment for Glioblastoma Multiforme (GBM) is comprised of surgery and adjuvant chemoradiation. Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated disease-modifying activity in GBM and holds great promise. Radiation, a standard-of-care treatment for GBM, has well-known immunomodulatory properties and may overcome the immunosuppressive tumor microenvironment (TME); however, radiation dose optimization and integration with CAR T cell therapy is not well defined. Murine immunocompetent models of GBM were treated with titrated doses of stereotactic radiosurgery (SRS) of 5, 10, and 20 Gray (Gy), and the TME was analyzed using Nanostring. A conditioning dose of 10 Gy was determined based on tumor growth kinetics and gene expression changes in the TME. We demonstrate that a conditioning dose of 10 Gy activates innate and adaptive immune cells in the TME. Mice treated with 10 Gy in combination with mCAR T cells demonstrated enhanced antitumor activity and superior memory responses to rechallenge with IL13Rα2-positive tumors. Furthermore, 10 Gy plus mCAR T cells also protected against IL13Rα2-negative tumors through a mechanism that was, in part, c-GAS-STING pathway-dependent. Together, these findings support combination conditioning with low-dose 10 Gy radiation in combination with mCAR T cells as a therapeutic strategy for GBM.

cell biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the synergistic effect and its mechanism between radiation and chimeric antigen receptor T - cell (CAR - T - cell) therapy in the treatment of glioblastoma multiforme (GBM). Specifically, the research aims to:

1. **Determine the optimal neoadjuvant radiation dose**: By using different doses of stereotactic radiosurgery (SRS), the researchers hope to find the optimal radiation dose that can modulate the tumor microenvironment (TME) without significantly affecting tumor growth.

2. **Evaluate the potential synergistic effect of conditional radiation and CAR - T - cell therapy**: The researchers hope to observe whether this combination can enhance the anti - tumor effect by combining conditional radiation with CAR - T - cell therapy and explore the underlying mechanism.

3. **Explore the effectiveness mechanism of the combination therapy**: The researchers hope to reveal the role of the c - GAS - STING pathway in enhancing the immune response by analyzing the changes in the TME after the combination therapy.

The paper carried out detailed experimental design and data analysis by using a GBM model with intact immune function in mice and IL13R α2 - specific CAR - T - cells to verify the above objectives. The study found that conditional radiation of 10 Gy can activate innate and adaptive immune cells, and when combined with CAR - T - cells, it can significantly improve anti - tumor activity and show a stronger memory response when rechallenged with IL13R α2 - positive tumors. In addition, 10 Gy plus CAR - T - cells can also protect against IL13R α2 - negative tumors through a mechanism partially dependent on the c - GAS - STING pathway. These results support the application of the treatment strategy of combining low - dose 10 Gy radiation with CAR - T - cells in GBM.